A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies

Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 TREMFYA is not approved in the U.S. for inhibition of structural damage.2f. ACR20 response is defined as both at least 20 percent improvement from baseline in the number of tender and number of swollen joints, and a 20 percent improvement from baseline in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure, visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein.15g. Dr. Mease is a paid consultant for Janssen. He has not been compensated for any media work.h. Radiographic progression is a key indicator of structural damage, which includes erosion and joint space narrowing. Radiographic progression is not in the FDA label for TREMFYA.2About the Network Meta-Analysis1A systematic literature review was conducted to identify randomized controlled trials up to February ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news